Literature DB >> 19152029

Stem cells downregulate the elevated levels of tissue plasminogen activator in rats after spinal cord injury.

Krishna Kumar Veeravalli1, Venkata Ramesh Dasari, Andrew J Tsung, Dzung H Dinh, Meena Gujrati, Dan Fassett, Jasti S Rao.   

Abstract

We investigated the involvement of tPA after SCI in rats and effect of treatment with human umbilical cord blood derived stem cells. tPA expression and activity were determined in vivo after SCI in rats and in vitro in rat embryonic spinal neurons in response to injury with staurosporine, hydrogen peroxide and glutamate. The activity and/or expression of tPA increased after SCI and reached peak levels on day 21 post-SCI. Notably, the tPA mRNA activity was upregulated by 310-fold compared to controls on day 21 post-SCI. As expected, MBP expression is minimal at the time of peak tPA activity and vice versa. Implantation of hUCB after SCI resulted in the downregulation of elevated tPA activity/expression in vivo in rats as well as in vitro in spinal neurons. Our results demonstrated the involvement of tPA in the secondary pathogenesis after SCI as well as the therapeutic potential of hUCB.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19152029     DOI： 10.1007/s11064-008-9894-3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN： 0364-3190            Impact factor:   3.996


  49 in total

1.  Brain tissue responses to ischemia.

Authors:  J M Lee; M C Grabb; G J Zipfel; D W Choi
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

2.  mRNAs encoding urokinase-type plasminogen activator and plasminogen activator inhibitor-1 are elevated in the mouse brain following kainate-mediated excitation.

Authors:  T Masos; R Miskin
Journal:  Brain Res Mol Brain Res       Date:  1997-07

Review 3.  Basic and clinical aspects of fibrinolysis and thrombolysis.

Authors:  D Collen; H R Lijnen
Journal:  Blood       Date:  1991-12-15       Impact factor: 22.113

4.  Release of plasminogen activator and a calcium-dependent metalloprotease from cultured sympathetic and sensory neurons.

Authors:  R N Pittman
Journal:  Dev Biol       Date:  1985-07       Impact factor: 3.582

5.  Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator.

Authors:  Y H Kim; J H Park; S H Hong; J Y Koh
Journal:  Science       Date:  1999-04-23       Impact factor: 47.728

6.  Neuroserpin, an axonally secreted serine protease inhibitor.

Authors:  T Osterwalder; J Contartese; E T Stoeckli; T B Kuhn; P Sonderegger
Journal:  EMBO J       Date:  1996-06-17       Impact factor: 11.598

7.  Rapid, activity-induced increase in tissue plasminogen activator is mediated by metabotropic glutamate receptor-dependent mRNA translation.

Authors:  Chan Y Shin; Mitchell Kundel; David G Wells
Journal:  J Neurosci       Date:  2004-10-20       Impact factor: 6.167

8.  Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function.

Authors:  M Ankarcrona; J M Dypbukt; E Bonfoco; B Zhivotovsky; S Orrenius; S A Lipton; P Nicotera
Journal:  Neuron       Date:  1995-10       Impact factor: 17.173

9.  Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination.

Authors:  W Cammer; B R Bloom; W T Norton; S Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

10.  Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.

Authors:  K Akassoglou; K W Kombrinck; J L Degen; S Strickland
Journal:  J Cell Biol       Date:  2000-05-29       Impact factor: 10.539
View more
  8 in total

Review 1.  Transplantation of umbilical cord blood stem cells for treating spinal cord injury.

Authors:  Dong-Hyuk Park; Jeong-Hyun Lee; Cesario V Borlongan; Paul R Sanberg; Yong-Gu Chung; Tai-Hyoung Cho
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

Review 2.  MMP-12, a Promising Therapeutic Target for Neurological Diseases.

Authors:  Bharath Chelluboina; Koteswara Rao Nalamolu; Jeffrey D Klopfenstein; David M Pinson; David Z Wang; Raghu Vemuganti; Krishna Kumar Veeravalli
Journal:  Mol Neurobiol       Date:  2017-02-02       Impact factor: 5.590

3.  Axonal regrowth after spinal cord injury via chondroitinase and the tissue plasminogen activator (tPA)/plasmin system.

Authors:  Noreen Bukhari; Luisa Torres; John K Robinson; Stella E Tsirka
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

Review 4.  Mesenchymal stem cells in the treatment of spinal cord injuries: A review.

Authors:  Venkata Ramesh Dasari; Krishna Kumar Veeravalli; Dzung H Dinh
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

5.  Stem cells for spinal cord regeneration: Current status.

Authors:  Zain A Sobani; Syed A Quadri; S Ather Enam
Journal:  Surg Neurol Int       Date:  2010-12-25

6.  Tuftsin promotes an anti-inflammatory switch and attenuates symptoms in experimental autoimmune encephalomyelitis.

Authors:  Muzhou Wu; Jillian C Nissen; Emily I Chen; Stella E Tsirka
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

Review 7.  Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies.

Authors:  Luisa R Galieva; Yana O Mukhamedshina; Svetlana S Arkhipova; Albert A Rizvanov
Journal:  Front Pharmacol       Date:  2017-09-08       Impact factor: 5.810

Review 8.  Translational Regenerative Therapies for Chronic Spinal Cord Injury.

Authors:  Kyriakos Dalamagkas; Magdalini Tsintou; Amelia Seifalian; Alexander M Seifalian
Journal:  Int J Mol Sci       Date:  2018-06-15       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.